Drug
Argx 121
Argx 121: highest development phase Phase 2, developed by Argenx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARGX-121 NCT07773727 | Phase 2 | Immunoglobulin A Nephropathy (IgAN) |
Latest
No recent events.
Follow Argx 121 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.